A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma
Clinical trial NCT04207086 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04207086
- Sponsor
- Melanoma Institute Australia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-11
- Primary completion
- 2023-01-31
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.